Circulating Aminoterminal Propeptide of Type III Procollagen as a Biomarker of Cardiovascular Events in Patients Undergoing Hemodialysis.
Ontology highlight
ABSTRACT: AIM:Type ? collagen abundantly exists in the cardiovascular system, including the aorta and heart. We prospectively investigated whether serum levels of aminoterminal propeptide of type ? procollagen (P?NP), a circulating biomarker of cardiovascular fibrosis, could predict cardiovascular events in patients undergoing hemodialysis. METHODS:Serum P?NP concentrations were measured in 244 patients undergoing maintenance hemodialysis (men, 126; women, 118; mean age, 64±11 years; dialysis duration, 11.5±7.8 years) by immunoradiometric assay in February 2005. The endpoint was cardiovascular events, and the patients were followed up until the endpoint was reached, or until January 31, 2011. RESULTS:During the follow-up for 4.7±1.8 years, cardiovascular events occurred in 78 (30.3%) of 244 patients. Stepwise Cox hazard analysis revealed that cardiovascular events were associated with increased serum P?NP concentration (1 U/mL; hazard ratio, 1.616; P=0.0001). The median serum P?NP concentrations were higher in patients with cardiovascular events than in those without (2.30±0.19 U/mL vs 1.30±0.03 U/mL; P?0.0001). When the patients were assigned to subgroups based on serum P?NP cut-off value for cardiovascular events of 1.75 U/mL, defined by receiver operating characteristic analysis, cardiovascular event-free survival rates at 5 years were lower (P=0.0001) in the subgroup of serum P?NP ?1.75 U/mL than in that of serum P?NP ?1.75 U/mL (31.9% vs 88.2%). CONCLUSIONS:Serum P?NP could be a new biomarker for predicting the cardiovascular events in patients undergoing hemodialysis.
SUBMITTER: Nishimura M
PROVIDER: S-EPMC6456459 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA